PEGylated amphiphilic polymeric manganese(II) complexes as magnetic resonance angiographic agents
Xiaoqin Liu,Shengxiang Fu,Chunchao Xia,Mengye Li,Zhongyuan Cai,Changqiang Wu,Fulin Lu,Jiang Zhu,Bin Song,Qiyong Gong,Hua Ai
DOI: https://doi.org/10.1039/d2tb00089j
IF: 7.571
2022-01-01
Journal of Materials Chemistry B
Abstract:Currently, the most commonly used clinical magnetic resonance imaging (MRI) contrast agents, Gd(III) chelates, have been found to be associated with nephrogenic systemic fibrosis (NSF) in renally compromised patients. Toxicity concerns related to Gd(III)-based agents prompted intensive research toward the development of safe, efficient, and long-cycle non-Gd contrast agents. Herein, three amphiphilic polymeric manganese (Mn) ligands (mPEG(1k)-P(L-a-HMDI)-mPEG(1k), mPEG(2k)-P(L-a-HMDI)-mPEG(2k) and mPEG(4k)-P(L-a-HMDI)-mPEG(4k)) were synthesized, and then end-capped respectively with different molecular weights of polyethylene glycol monomethyl ether (mPEG 1 kD, 2 kD and 4 kD) to obtain amphiphilic polymer Mn ligands. After being chelated with Mn(II), these amphiphilic polymer Mn complexes show significantly higher T-1 relaxivity than the small molecule Mn complex (MnL) at 0.5 T, 1.5 T and 3.0 T magnetic fields, respectively. Then, mPEG(2k)-P(MnL-a-HMDI)-mPEG(2k )with relatively high T-1 relaxivities (23.2, 14.4 and 9.7 mM(-1) s(-1) at 0.5 T, 1.5 T and 3.0 T, respectively), low CMC (4.7 mg L-1), reasonable size (48 nm) and excellent stability among these three polymer Mn complexes was selected for in vivo MR imaging of vascular vessels. The results suggest that mPEG(2k)-P(MnL-a-HMDI)-mPEG(2k) has an excellent and relatively long time-window vascular enhancement effect even at a low dose of 0.05 mmol Mn kg(-1) BW, and could Way a role in the diagnosis of vascular diseases (0.1 mmol Mn kg(-1) BW). Therefore, mPEG 2k -P(MnL-a-HMDI)-mPEG(2k) may be considered as a potential blood pool contrast agent.